Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Mototsugu Shimokawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8140-4565; OpenAlex author ID A5017789799, A5026894415. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 9 papers · 2024: 4 papers · 2025: 6 papers · 2026: 6 papers

Papers 32

  1. Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folini… Co-author DOI 10.1002/ijc.70072↗
  2. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  3. Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluor… Co-author DOI 10.1177/17588359261442386↗
  4. Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic ac… Co-author DOI 10.1186/s12885-026-16237-2↗
  5. Dynamic analysis of C-reactive protein/albumin ratio in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-8417823/v1↗
  6. Adjuvant S-1 Plus Metformin after Pancreatic Cancer Resection: A Multicenter Randomized Phase II Trial Last author DOI 10.21203/rs.3.rs-9445035/v1↗
  7. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… First author DOI 10.1016/j.esmogo.2025.100150↗
  8. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  9. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Co-author DOI 10.1177/17588359251320768↗
  10. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… Co-author DOI 10.1177/17588359251393156↗
  11. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  12. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  13. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or ge… Co-author DOI 10.1038/s41598-024-55673-7↗
  14. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  15. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  16. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  17. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Co-author DOI 10.1007/s10147-023-02354-6↗
  18. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  19. Impact on the image quality of modified reduced field-of-view diffusion-weighted magnetic resonance imaging of pancreatic adenocarcinoma using spatially tailor… Co-author DOI 10.1016/j.ejrad.2023.111138↗
  20. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-… Co-author DOI 10.1038/s41598-023-34962-7↗
  21. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  22. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Co-author DOI 10.1159/000527176↗
  23. A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0288033↗
  24. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  25. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Co-author DOI 10.21873/anticanres.16335↗
  26. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… Co-author DOI 10.1016/j.jgo.2021.06.011↗
  27. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multi… Co-author DOI 10.1186/s12885-021-09139-y↗
  28. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  29. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  30. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗
  31. Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by t… Co-author PMID 27069182↗
  32. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-014-4280-7↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 25 shared papers, 2021–2026 · strength 3.76
  2. Kenji Mitsugi · 25 shared papers, 2021–2026 · strength 3.76
  3. Shiho Arima · 25 shared papers, 2021–2026 · strength 3.76
  4. Futa Koga · 25 shared papers, 2021–2026 · strength 3.76
  5. Taiga Otsuka · 25 shared papers, 2021–2026 · strength 3.76
  6. Tsuyoshi Shirakawa · 25 shared papers, 2021–2026 · strength 3.76
  7. Hiroki Taguchi · 25 shared papers, 2021–2026 · strength 3.76
  8. Taro Shibuki · 21 shared papers, 2021–2026 · strength 2.96
  9. Azusa Komori · 21 shared papers, 2021–2026 · strength 2.96
  10. Yasunori Kawaguchi · 16 shared papers, 2021–2026 · strength 2.60
  11. Yasushi Ide · 17 shared papers, 2021–2026 · strength 2.48
  12. Kazuo Nishikawa · 14 shared papers, 2023–2026 · strength 2.38
  13. Shuji Arita · 14 shared papers, 2023–2026 · strength 2.38
  14. Masaru Fukahori · 14 shared papers, 2021–2025 · strength 1.85
  15. Keisuke Miwa · 11 shared papers, 2023–2026 · strength 1.72
  16. Norio Ureshino · 13 shared papers, 2021–2025 · strength 1.68
  17. Akio Ido · 7 shared papers, 2021–2026 · strength 0.93
  18. Yoshinobu Okabe · 7 shared papers, 2021–2024 · strength 0.91
  19. Tomonori Araki · 4 shared papers, 2025–2026 · strength 0.73
  20. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  21. Keishi Sugimachi · 2 shared papers, 2023 · strength 0.31
  22. Tomoharu Yoshizumi · 2 shared papers, 2023 · strength 0.31
  23. Eishi Baba · 2 shared papers, 2023–2024 · strength 0.30
  24. Takeshi Sudo · 1 shared paper, 2026 · strength 0.23
  25. Yutaka Itoh · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.